Objectives: To investigate the effects of b b-adrenergic stimulation on IL-6 secretion in humans, and to determine the potential contribution to this response of adipocytes and peripheral blood cells (PBC). Design: Experimental study in 8 human volunteers, and in vitro studies on murine adipocyte cell-line, 3T3.L1 and 3T3.F442A, and human PBC. Measurements: Plasma IL-6 and TNFa responses to isoprenaline infusion. Cytokine secretion from differentiated adipocyte cell-lines and PBC in response to isoprenaline. Results: Plasma IL-6 levels increased ninefold (median) by 180 min (baseline median 0.51 [interquartile range 0.47 ± 1.4] vs 180 mins 4.53 [2.58 ± 5.69] pg ml 71 , P 0.01). One hour after infusion, IL-6 levels (2.9 [1.27 ± 3.98]) were lower than at 180 min (P 0.05), but higher than baseline (P 0.01). TNFa levels were unchanged. Differentiated adipocytes incubated in isoprenaline (0 ± 0.1 mM) released signi®cantly increased amounts of IL-6 whereas no response was elicited from PBC. Conclusions: The induction of IL-6 observed in vivo may be attributed to the b b-adrenergic stimulation of IL-6 release speci®cally from adipocytes, as opposed to circulating blood cells.
Introduction
Interleukin-6 (IL-6) is the most abundant cytokine in plasma and its secretion is known to increase during sympathetic activation. However, the tissue origin of the sympathetic-mediated increase in circulating IL-6 has been less clear, partly due to the widespread tissue distribution of this cytokine. We have shown that IL-6 is expressed in, and released by, human subcutaneous adipose tissue, and estimate that adipose tissue is likely to contribute signi®cantly to the plasma pool of IL-6. 1, 2 This raises the question, in turn, of how adipose tissue IL-6 expression and release are regulated, and whether adipose tissue may account, in part, for the increased circulating IL-6 levels observed following sympathetic stimulation. The present study was performed to address this question. , and % body fat (by electrical bioimpedance) was 24.5 [17.9 ± 26.3]%. Isoprenaline was infused at a rate beginning at 0.5 mgamin 71 , and increased in increments in order to elicit a steady state biological response in all subjects of heart rate b 100 but`twice resting heart rate. Infusions were maintained for 3 h, followed by a 1 h`recovery' period. PBC were obtained from the buffy coat of the whole blood. Adipocytes were differentiated as previously described. 3 Cells were incubated in isoprenaline 0 ± 0.1 mM for 4 h and supernatants were assayed for IL-6 by ELISA (R&D Systems, Abingdon, UK).
Methods

Results
Plasma IL-6 levels had risen signi®cantly after 150 min of intravenous isoprenaline, infusion, and reached their maximum at 180 min (baseline 0.51 [0.47 ± 1.4] vs 150 min 3.40 [2.34 ± 5.17], P 0.01, and vs 180 min 4.53 [2.58 ± 5.69] pg ml 71 , P 0.01). One hour after infusion, IL-6 levels (2.9 [1.27 ± 3.98]) were signi®cantly lower than at 180 min (P 0.05), but remained higher than baseline (P 0.01) ( Figure  1 . No change was observed in plasma TNFa levels. Adipocytes incubated in isoprenaline (0 ± 0.1 mM) released increased amounts of IL-6 into supernatants compared to baseline (P 0.02), whereas no signi®-cant response was elicited from PBC.
Discussion
These results demonstrate that non-speci®c b-activation substantially elevates IL-6 secretion in humans in vivo, consistent with the proposed role of IL-6 in the stress response. Importantly, the in vitro studies suggest tissue-speci®c differences in the adrenergic regulation of IL-6 release, and raise the possibility that release of IL-6 from adipose tissue, as opposed to macrophages, may signi®cantly contribute to the rise in plasma IL-6 in response to isoprenaline. While the physiological consequences of the suggested rise in adipose tissue IL-6 release remain to be clari®ed, this observation has intriguing implications for the role of sympathetic activation in adipose tissue. Thus, not only may sympathetic activation promote lipolysis and suppresson of leptin production, 4 but it may also elicit a concomitant acute rise in plasma IL-6, suggesting an additional endocrine pathway though which adipose tissue may in¯uence energy metabolism at distant sites. 
